Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study
Chia-Chi Lin(National Taiwan University Hospital), Yeong‐Shiau Pu(National Taiwan University Hospital), Chao‐Yuan Huang(Chung Shan Medical University), Yu‐Chieh Tsai(Chang Bing Show Chwan Memorial Hospital), Chih‐Hung Hsu(National Taiwan University of Science and Technology), Ann‐Lii Cheng(National Taiwan University), Hsiao-Yi Keng(National Taiwan University), Kuo‐How Huang(National Taiwan University)
Cited by 39
Related Papers
The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k